neues aus san antonio 2017...with her2‐positive early breast cancer after 5 years’...
TRANSCRIPT
![Page 1: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/1.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Neues aus San Antonio2017
Therapie des frühen Mammakarzinoms(neo‐)adjuvant
C.A. Hanusch
![Page 2: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/2.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Topics 1
• GS3‐05: Survival analysis of the prospectively randomized phase III GeparSepto trial
• GS3‐04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeksversus 1 year, combined with adjuvant taxane‐anthracycline chemotherapy, for earlyHER2‐positive breast cancer (the SOLD study).
• Incidence and management of diarrhea with adjuvant Pertuzumaband Trastuzumab in HER2‐positive breast cancer
![Page 3: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/3.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Topics 2• Pharmacokinetic results of a subcutaneous injection of Trastuzumab into the thigh versus into the abdominal wall in patients with HER2‐positive primary breast cancer (BC) treated within the neo‐/adjuvant GAIN‐2 study
• Efficacy and safety of subcutaneous or intravenous Trastuzumab in patients with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH study
• A phase Ib dose‐finding study of subcutaneous Pertuzumab in combination with subcutaneous Trastuzumab in healthy male volunteers and female patients with early breast cancer
![Page 4: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/4.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
GS3‐05: Survival analysis of the prospectively randomized phase III GeparSepto trial
GeparSepto: Überträgt sich die signifikant höhere pCR Rate mit nab-Pac in ein besseres DFS?
![Page 5: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/5.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
![Page 6: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/6.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
![Page 7: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/7.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
![Page 8: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/8.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
![Page 9: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/9.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
![Page 10: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/10.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
![Page 11: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/11.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
![Page 12: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/12.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
![Page 13: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/13.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
![Page 14: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/14.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Schneeweiss A, et al. SABCS 2017 (GS3-05)
![Page 15: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/15.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
pCR Rate gesteigert mit nabPaclitaxel vs. lösl. Paclitaxel als Teil einer sequenziellen Anthracyclin/Taxan‐basierten Chemotherapie
Höhere pCR‐Rate übersetzt sich in ein signifikant und klinisch relevant verbessertes rezidivfreiesÜberleben (HR=0.69, log rank p=0.0044)
Auch Pat. mit Ki67 <20% bzw. non‐pCR profitieren bez. DFS von nab‐Paclitaxel
Rate peripherer Neuropathien unter nabPaclitaxel nach Dosisreduktion gesenkt:Grad ¾: 150/ 125 (mg/m2 KOF) 15%/ 8% (nach 464 rekrutierten Pat.)
Fazit
![Page 16: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/16.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
A randomized phase III study of adjuvant Trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant Taxane‐Anthracycline chemotherapy, for
early HER2‐positive breast cancer The Synergism Or Long Duration (SOLD)
trialJoensuu H et al. Oral Session – General Session 3
Abstract No. GS3‐04
![Page 17: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/17.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Hypothesis
Administration of Trastuzumab concomitantly with a Taxane for a brief time period is not inferior in terms of DFS as compared with the standard treatment*, and may be less cardiotoxic
*Standard: Chemotherapy plus 12 months of anti‐HER2‐directed treatment ± endocrine therapy
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0417
![Page 18: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/18.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Design
*Wkly iv, or 3‐wkly either iv or sc; **14 times 3 weekly, either iv or sc
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
In both groups:
• Locoregional RT given according to the institutional practice
• Endocrine therapy for a minimum of 5 yrs when cancer ER/PR + ve
Docetaxel (D)
80/100 mg/m2
iv 3‐wkly
F600E75C600iv 3‐wkly
Trastuzumab (T)
T for 9 wks*
T for 9 wks* T to complete 1 year of administration**
DFEC
D D
D D D
FEC
FEC
FEC
FEC
FEC
R
18
![Page 19: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/19.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Patient disposition
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0419
Category 9 weeksno. (%)
1 yearno. (%)
Randomized (Jan 2008 to Dec 2014) 1,087 1,089
Included ITT Population* 1,085 1,089
Withdrew consent 0 (0) 0 (0)
Had distant metastases at study entry 2 (0) 0 (0)
Received study treatment (Safety Population) 1,084 1,089
*ITT, Intention to treat
![Page 20: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/20.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Key baseline characteristics
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0420
Characteristic 9-week group(n=1,085)
1-year group(n=1,089)
Median age (range) – years (range) 56 (23-82) 56 (27-79)
Premenopausal 33% 33%
Breast tumor diameter≤10 mm 12% 14%11-21 mm 44% 42%21-50 mm 41% 42%>50 mm 3% 3%
Axillary lymph nodes with cancer0 60% 60%1-3 30% 29%>3 11% 11%
Ductal histological type 92% 92%Estrogen receptor-positive 66% 66%Progesterone receptor-positive 46% 47%
![Page 21: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/21.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – DFS events and deaths (ITT)
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0421
Event9-wk group(n=1,085)
n (%)
1-yr group(n=1,089)
n (%)Any recurrence or death 140 (13) 105 (10)
Distant recurrence 73 (7) 61 (6)Locoregional recurrence 17 (2) 13 (1)Contralateral BC 15 (1) 7 (1)Second cancer 27 (3) 24 (2)Death without cancer 14 (1) 5 (0)
Death from any cause 58 (5) 44 (4)Death from BC 34 (3) 33 (3)Death from another cause 24 (2) 11 (1)
![Page 22: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/22.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Disease‐free survival
22 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
Alive, norecurren
ce(%
)
90.5%*
88.0%*
HR 1.39 (90% Cl 1.12‐1.72)
Non‐inferiority could not be demonstrated
51 weeks9 weeks
Years
Non‐inferiority margin 1.385
Hazard Ratio
• Chemo: 3 x Doc q3w 3 x FEC q3w, N=2,176
• Non‐inferiority instead of superiority study design
*5‐year DFS estimate
Number at risk10851089
10131047
707742
373394
7682
00
0 2 4 6 8 10 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
0
20
40
60
80
100
![Page 23: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/23.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Overall survival
23 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
Prop
ortio
n alive(%
)
Number at risk10851089
10471078
761786
408421
8187
00
95.9%*
94.7%*
HR 1.36 (90% Cl 0.98‐1.89)
Years
*5‐year survival estimate
51 weeks9 weeks
![Page 24: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/24.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
HR 1.24 (90% Cl 0.93‐1.65)
SOLD – Distant disease‐free survival
24 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
94.2%*
93.2%*Prop
ortio
n with
outd
istant
recurren
ce(%
)
*5‐year DDFS estimate
51 weeks9 weeks
YearsNumber at risk
10851089
10251056
723760
393409
8083
00
![Page 25: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/25.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Subgroup Hazard Ratio(90% Cl)
p (interaction)
ER status NegativePositive
1.57 (1.14‐2.17)1.28 (0.96‐1.69) 0.424
Docetaxel dose 80 mg/m2
100 mg/m21.66 (1.30‐2.11)0.67 (0.41‐1.10) 0.007
Nodes with cancer 01‐33+
1.31 (0.95‐1.80)1.83 (1.22‐2.74)1.24 (0.82‐1.85) 0.460
Centre accrual <100 patients≥100 patients
1.40 (1.06‐1.83)1.37 (0.98‐1.93) 0.949
Age <50 yrs≥50 yrs
1.08 (0.76‐1.53)1.61 (1.23‐2.11) 0.137
Stage IIIIII
1.46 (0.96‐2.22)1.54 (1.12‐2.11)1.21 (0.81‐1.79) 0.724
SOLD – Predefined subgroup analyses for DFS
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0425
Favors 9 weeks Favors 1-year10.5 1.5 20 2.5 3
![Page 26: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/26.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Prop
ortio
n alivewith
outrecurrence(%
)
SOLD – DFS: Docetaxel dose 80 mg/m2
26 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
91.3%*
86.8%*
HR 1.66 (90% Cl 1.30‐2.11)
YearsNumber at risk843835
765808
545568
309317
7077
00
*5‐year DFS estimate
51 weeks9 weeks
![Page 27: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/27.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – DFS: Docetaxel dose 100 mg/m2
27 Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
92.2%*
87.8%*
242254
228239
162174
6477
55
00
Prop
ortio
n alivewith
outrecurrence(%
)
*5‐year DFS estimate
51 weeks9 weeks
Number at risk
HR 0.71 (90% Cl 0.44‐1.14)
Years
![Page 28: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/28.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
• Chemotherapy‐related toxicity generally similar and expected in the 2 groups
SOLD – Treatment safety
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
9-weekgroupn (%)
1-yeargroupn (%)
Discontinued Chemotherapy 44 (4.1) 51 (4.7)
Discontinued Trastuzumab 96 (8.9)-53% for toxicity
217 (19.9)-66% for toxicity
Died from treatment-related cause 2 (0.2) 2 (0.2)
28
![Page 29: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/29.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
• Less cardiac toxicity was observed in the 9‐week group
SOLD – Cardiac safety
*Any Gr. 3 or 4 cardiac event; symptomatic cardiac failure; cardiac failure requiring medical management; LVEF decrease >10 percentage points and to a value <50%; LVEF decrease to <45% from any baseline value,
** p=0.012; ***p=0.046
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
Event 9-week groupn (%)
1-year groupn (%)
Any protocol-defined cardiac adverse event* 22 (2.0) 42 (3.9)**
Congestive heart failure 21 (1.9) 36 (3.3)***
29
![Page 30: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/30.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Mean LVEF stratified by the treatmentgroup
LVEF, Left ventricular ejection fraction
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐04
LVEF (%
)
p<0.001
Time after study entry
9 weeks
51 weeks
30
![Page 31: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/31.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
SOLD – Conclusions
• Non‐inferiority of 9‐weeks of adjuvant Trastuzumab plus Chemotherapy could not be demonstrated as compared to 1‐year of Trastuzumab plus Chemotherapy in terms of DFS
• Patients treated with the 9‐week duration had fewer cardiac events and had the LVEF better maintained
• Docetaxel dosing with Trastuzumab requires further study• Chemotherapy plus 1‐year of anti‐HER2 therapy should remain the standard
Mod. Joensuu H et al. SABCS 2017, Oral Session – General Session 3, Abstract No. GS3‐0431
![Page 32: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/32.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Incidence and management of diarrheawith adjuvant Pertuzumab and
Trastuzumab in HER2‐positive breast cancer
Bines J et al. Poster Session 1 – Treatment: Adjuvant Therapy
Abstract No. P1‐13‐07
![Page 33: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/33.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Mod. Bines J et al. SABCS 2017, Poster Session 1 – Treatment: Adjuvant Therapy, Abstract No. P1‐13‐0733
APHINITY – Inzidenz der Diarrhoe nachTherapiezyklus
De Azambuja E et al., SABCS 2017
Targeted treatment cycle
Percen
tage of p
atients w
ith an even
t
Pertuzumab + Trastuzumab + Chemotherapy
Placebo + Trastuzumab + Chemotherapy
2,3642,335
2,2532,241
2,2332,225
2,2652,257
1,6581,700
2,1852,190
2,0512,051
2,3062,302
2,2462,231
2,3292,317
2,2852,281
2,2102,211
2,1932,194
2,1512,169
2,1362,159
2,1092,129
2,1652,178
2,2002,200
No. at risk
![Page 34: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/34.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
APHINITY – Inzidenz der Diarrhoe nach Therapiezyklus und Art der Chemotherapie
Mod. Bines J et al. SABCS 2017, Poster Session 1 – Treatment: Adjuvant Therapy, Abstract No. P1‐13‐0734
De Azambuja E et al., SABCS 2017
Targeted treatment cycle
1,8341,824528510
1,7551,751496489
1,7411,742490482
1,7641,765499491
1,3121,336345364
1,7031,713480476
1,6081,602441448
1,7981,806506495
1,7511,744493486
1,8131,815514501
1,7831,788500492
1,7211,730487480
1,7081,716483477
1,6771,692472476
1,6661,685468473
1,6461,659461469
1,6891,701474476
1,7131,719485480
No. at risk
Pertuzumab + Trastuzumab + Anthracycline
Placebo + Trastuzumab + Anthracycline
Pertuzumab + Trastuzumab + Non‐Anthracycline
Placebo + Trastuzumab + Non‐Anthracycline
Percen
tage of p
atients w
ith an even
t
![Page 35: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/35.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
APHINITY – Inzidenz und Management der Diarrhoe
Mod. Bines J et al. SABCS 2017, Poster Session 1 – Treatment: Adjuvant Therapy, Abstract No. P1‐13‐0735
De Azambuja E et al., SABCS 2017All presented data based on the preferred term “diarrhea“; *The incidence of diarrhea is based on anthracycline‐based chemotherapy only as no Pertuzumab or Placebo was given concurrently with an
Anthracycline. ¹Docetaxel only in the Non‐Anthracycline groups.
Anthracycline-based chemotherapy Non-Anthracycline-based chemotherapy
Pertuzumab + Trastuzumab n=1,834
Placebo + Trastuzumab n=1,894
Pertuzumab + Trastuzumab n=528
Placebo + Trastuzumab n=510
Incidence and severityTotal number of patients with at least one event (%) 1,235 (67.3) 772 (40.8) 447 (84.7) 314 (61.6)Total number of events 2,527 1,282 883 508Total number of patients with at least one NC1-CTCAE grade ≥3 event (%) 137 (7.5) 59 (3.1) 95 (18.0) 31 (6.1)
Total number of NCI-CTCAE grade ≥3 events 147 60 113 35Treatment period, total number of patients with at least one event (%)Anthracycline* 296 (16.1) 278 (14.7) – –HER2-targeted therapy + Taxane¹ 1,006 (54.9) 513 (27.1) 444 (84.1) 301 (59.0)HER2-targeted treatment post-chemotherapy 373 (20.3) 175 (9.2) 55 (10.4) 46 (9.0)
![Page 36: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/36.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Safety of adjuvant treatment with Pertuzumab plus Trastuzumab after neoadjuvant Anthracycline‐based
chemotherapy in patients with HER2‐positive localized breast cancer: Updated results from the
BERENICE study
Dang C et al. Poster Session 5 – Treatment: Her2‐targeted therapy
Abstract No. P5‐20‐04
![Page 37: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/37.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Cohort A(ddAC TPH)
Cohort B(FEC DPH)
Overalltreatment period n=199
Adjuvant treatment period n=181
Overall treatment period n=198
Adjuvant treatment period n=190
Any AE 198 (99.5) 171 (94.5) 198 (100.0) 171 (90.0)Grade ≥3 AE 109 (54.8) 23 (12.7) 126 (63.6) 40 (21.1)Serious AE 54 (27.1) 15 (8.3) 61 (30.8) 17 (8.9)
AE leading to P or H discontinuation 19 (9.5) 9 (5.0) 14 (7.1) 11 (5.8)
Diarrhea (any grade) 144 (72.4) 26 (14.4) 148 (74.7) 45 (23.7)Diarrhea (grade ≥3) 6 (3) 0 (0) 22 (11.1) 2 (1.1)
Mod. Dang C et al. SABCS 2017, Poster Session 5 – Treatment: Her2‐targeted therapy, Abstract No. P5‐20‐04 37
BERENICE StudieAdjuvantes Trastuzumab/Pertuzumab nach anthrazyklinhaltiger NACT (ddAC q2w Pacli q1w vs. FEC q3w Docetaxel q3w, N=397)
Data are number of patients (%).AE. adverse events; ddAC. dose‐dense Doxorubicin plus Cyclophosphamide; DPH. Docetaxel. Pertuzumab. and Trastuzumab; FEC. Fluorouracil. Epirubicin. and Cyclophosphamide; TPH. Paclitaxel,
Pertuzumab. and Trastuzumab.
General AEs (safety population)
![Page 38: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/38.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message
38
• Die Rate der Diarrhoe unter CTX plus Trastuzumab + Pertuzumab ist im Vgl. zu Trastuzumab erhöht
• Erhebliche Verbesserung nach Absetzen der CTX• APHINITY: Gesteigerte Diarrhoe unter Anthrazyklin‐freier CTX durch den alleinigen Einsatz von Docetaxel bedingt
![Page 39: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/39.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Pharmacokinetic results of a subcutaneous injection of Trastuzumab into the thigh versus into the abdominal wall in patients with HER2‐positive primary breast cancer (BC) treated within the neo‐/adjuvant GAIN‐2 study
Möbus V et al. Poster Session 5 – Treatment: Her2‐targeted therapyAbstract No. P5‐20‐09
![Page 40: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/40.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
40
GAIN‐2 StudiePK Resultate s.c. Applikation von Trastuzumab
Mod. Möbus V et al. SABCS 2017, Poster Session 5 – Treatment: Her2‐targeted therapy, Abstract No. P5‐20‐09
N=2886
Neo
‐/Ad
juvant
(∑ 100
0 pa
ents)
Trastuzumab i.v.**
Pertuzumab i.v.*
Pertuzumab i.v.*
Trastuzumab i.v.**
EpirubicinStarting dose. 90 mg/m² q2wDose levels (min./max.)‐ Level – 3: 38 mg/m² q2w‐ Level + 2: 120 mg/m² q2w
CyclophosphamideStarting dose: 600 mg/m² q2wDose levels (min./max.)‐ Level – 3: 450 mg/m² q2w‐ Level +2: 1200 mg/m² q2w
DocetaxelStarting dose: 75 mg/m² q2wDose levels (min./max.)‐ Level – 1: 60 mg/m² q2w‐ Level + 2: 100 mg/m² q2w
Epirubicin150 mg/m²
q2w
nab‐Paclitaxel330 mg/m²
q2w
Cyclophos‐phamide
2000 mg/m² q2w
N=220
1 week
rest
*Pertuzumab i.v.(if HER2‐positive and neoadjuvant): Starting dose 840 mg q3w, thereafter 420 mg q3w.
**Trastuzumab i.v.(if HER2‐positive and neoadjuvant or adjuvant): Starting dose 8 mg/kg BW q3w, thereafter 6 mg/kg BW q3w
***Therapy durationTrastuzumab i.v. and s.c. totally 1 year
E E E nP nP nP C C C
E E ED D D D
R
EC C C C
3 weeks
Trastuzumab s.c.Thigh
Trastuzumab s.c.Abdominal wall
Trastuzumab s.c.600 mg q3w***
Trastuzumab s.c.600 mg q3w.***
R
![Page 41: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/41.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Mod. Möbus V et al. SABCS 2017, Poster Session 5 – Treatment: Her2‐targeted therapy, Abstract No. P5‐20‐09 41
GAIN‐2 Studie – PK Resultate s.c. Applikation von Trastuzumab
Mean plasma concentration‐time profile of the s.c. Trastuzumab
Concen
tration (ug/ml)
Time (days)
Thigh
Abdw
![Page 42: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/42.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message – GAIN‐2
42
• Bestätigung der besseren Bioverfügbarkeit und daraus resultierenden Plasmaspiegel nach Applikation von TrastuzumabSC in den Oberschenkel vs. die Bauchdecke
• Damit Bestätigung der Zulassung von Trastuzumab SC
![Page 43: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/43.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Efficacy and safety of subcutaneous or intravenous Trastuzumab in patients with HER2‐positive early
breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label,
randomized HannaH study
Jackisch C et al., Poster Discussion – Novel Drugs / Predicting Response for HER2+ Breast Cancer
Abstract No. PD3‐11
![Page 44: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/44.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
HannaH Trial – Trastuzumab s.c., 5‐J‐FU, finale AnalyseEFS by tpCR status (ITT population)
Mod. Jackisch C et al. SABCS 2017, Poster Discussion – Novel Drugs / Predicting Response for HER2+ Breast Cancer, Abstract No. PD3‐11
EFS, event‐free‐survival; H IV, intravenous Trastuzumab; H SC, subcutaneous Trastuzumab: ITT, intent‐to‐treat population: tpCR, total pathologic complete response
TreatmentH IV / tpCRH SC / tpCRH IV / non‐tpCRH SC / non‐tpCR
Estim
ated
Proba
bility
Months
94203108186
51524244
93170105159
741077992
70997687
7612486116
8114398133
0000
No. at risk
6‐year event‐free rate (95% Cl)
H IV H SC
tpCR 0.83(0.76, 0.91)
0.82(0.74, 0.89)
No tpCR 0.57(0.49, 0.64)
0.54(0.47, 0.62)
44
![Page 45: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/45.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message – HannaH
45
• Überlebensvorteil (EFS/OS) nach pCR bestätigt• Konsistente Resultate hinsichtlich der Äquieffektivität von Trastuzumab s.c. vs. i.v.
• Keine neuen Safety‐Signale
![Page 46: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/46.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
A phase Ib dose‐finding study of subcutaneous Pertuzumab in combination with subcutaneous Trastuzumab in healthy male volunteers and female patients with early breast cancer
Kirschbrown WP et al. Poster Session – 5 Treatment: Her2‐targeted therapy (presenter:
Whitney P)Abstract No. P5‐20‐07
![Page 47: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/47.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Take Home Message – Pertuzumab s.c.
47
• Pertuzumab s.c. ähnliche PK wie Pertuzumab i.v.• Kombination von Pertuzumab s.c. und Trastuzumab s.c. ohne beeinträchtigende Wirkung aufeinander
• Phase‐3‐Studie mit dualer Blockade s.c. als fixe Dosis in Planung– FPI Juni 2018
![Page 48: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/48.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018
Vielen Dank für Ihre Aufmerksamkeit!
![Page 49: Neues aus San Antonio 2017...with HER2‐positive early breast cancer after 5 years’ treatment‐free follow‐up: Final analysis from the phase III, open‐label, randomized HannaH](https://reader033.vdocument.in/reader033/viewer/2022042009/5e7153b45861134a9343d1bd/html5/thumbnails/49.jpg)
ONKOLOGIEFrauenklinik Taxisstraße
2018